Generic drug maker Impax Laboratories Inc. is challenging the patents of Avanir Pharmaceuticals Inc.’s Nuedexta as it tries to launch a lower-cost version of the drug.
Alameda-based Impax (NASDAQ: IPXL) said Wednesday that it has filed an abbreviated new drug application with the Food and Drug Administration for its version of Nuedexta, which treats pseudobulbar affect. PBA, as it is known, appears in some people with underlying neurologic conditions, causing involuntary, sudden and frequent episodes of laughing or crying.
No comments:
Post a Comment